This Dec. 4, 2017, file photo shows the Pfizer company logo at the company's headquarters in New York. Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline of targeted cancer medicines in development and a portfolio of other medicines that are expected to generate significant royalties over time. (AP Photo/Richard Drewm Fuke, File)
Featured Photo Galleries
